ANIXA BIOSCIENCES INC Shares Outstanding 2006-2021 | ANIX

ANIXA BIOSCIENCES INC shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ANIXA BIOSCIENCES INC Annual Shares Outstanding
(Millions of Shares)
2020 22
2019 20
2018 18
2017 12
2016 9
2015 9
2014 9
2013 8
2012 7
2011 7
2010 6
2009 6
2008 5
2007 4
2006 4
2005 4
ANIXA BIOSCIENCES INC Quarterly Shares Outstanding
(Millions of Shares)
2021-07-31 30
2021-04-30 29
2021-01-31 25
2020-10-31 22
2020-07-31 23
2020-04-30 21
2020-01-31 21
2019-10-31 20
2019-07-31 20
2019-04-30 20
2019-01-31 19
2018-10-31 18
2018-07-31 18
2018-04-30 17
2018-01-31 17
2017-10-31 12
2017-07-31 15
2017-04-30 10
2017-01-31 9
2016-10-31 9
2016-07-31 9
2016-04-30 9
2016-01-31 9
2015-10-31 9
2015-07-31 9
2015-04-30 9
2015-01-31 9
2014-10-31 9
2014-07-31 11
2014-04-30 9
2014-01-31 8
2013-10-31 8
2013-07-31 8
2013-04-30 8
2013-01-31 7
2012-10-31 7
2012-07-31 7
2012-04-30 7
2012-01-31 7
2011-10-31 7
2011-07-31 7
2011-04-30 7
2011-01-31 6
2010-10-31 6
2010-07-31 6
2010-04-30 6
2010-01-31 6
2009-10-31 6
2009-07-31 6
2009-04-30 5
2009-01-31 5
2008-10-31 5
2008-07-31 5
2008-04-30 5
2008-01-31 5
2007-10-31 4
2007-07-31 4
2007-04-30 4
2007-01-31 4
2006-10-31 4
2006-07-31 4
2006-04-30 4
2006-01-31 4
2005-10-31 4
2005-07-31 4
2005-04-30 3
2005-01-31 3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.130B $0.000B
Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57